Ca(2+)-dependent enhancement of [3H]noradrenaline uptake in PC12 cells through calmodulin-dependent kinases

Brain Res. 1998 Nov 2;809(2):155-64. doi: 10.1016/s0006-8993(98)00850-6.

Abstract

Ca(2+)-dependent regulation of [3H]noradrenaline ([3H]NA) uptake through the NA transporter was studied using PC12 cells. Preincubation for 10 min in the presence of 0.3-10 mM ca2+ in Krebs-Ringer (KR) buffer induced marked enhancement of the uptake (at 1 mM Ca2+, 6.6 times greater than that observed in the absence of Ca2+), which reflected both an increase in Vmax and a decrease in K(m) of the uptake process. Preincubation with 1 mM Ca2+ also induced a significant increase in the Bmax and Kd of [3H]desipramine binding. The uptake was still enhanced after washing cells with Ca(2+)-free buffer following preincubation with 1 mM Ca2+. 1-[N, O-bis(5-Isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62), 2-[N-(2-hydroxyethyl)-N-(4-methoxybenzenesulfonyl)]amino-N-(4-c hlo rocinnamyl) -N-methylbenzylamine (KN-93) (inhibitors of Ca2+/calmodulin-dependent kinase II), N-(6-aminohexyl)-5-chloro-1-naphthalenesulonamide (W-7) (a calmodulin antagonist), wortmannin (a myosin light chain kinase inhibitor) significantly reduced Ca(2+)-dependent enhancement of the uptake. Mycalolide B (an inhibitor of actin-myosin interaction) also inhibited the enhancement. Although calphostin C (a protein kinase C (PKC) inhibitor) did not affect the enhancement, 12-o-tetradecanoylphorbol 13-acetate (TPA) inhibited the uptake. A synthetic peptide with a sequence (KKVIYKFFS579 IRGSLW) contained in the intracellular COOH-terminal domain of a rat NA transporter was phosphorylated by purified brain Ca2+/calmodulin-dependent protein kinase II. These results suggest that Ca(2+)-dependent enhancement of the [3H]NA uptake in PC12 cells are mediated by activation of calmodulin-dependent protein kinases, probably through stimulation of translocation of the NA transporter to the plasma membrane and/or direct phosphorylation of the transporter itself.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Amino Acid Sequence
  • Androstadienes / pharmacology
  • Animals
  • Biological Transport / drug effects
  • Calcium / pharmacology*
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium-Calmodulin-Dependent Protein Kinases / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinases / metabolism*
  • Calmodulin / antagonists & inhibitors
  • Carcinogens / pharmacology
  • Carrier Proteins / metabolism*
  • Cytochalasin D / pharmacology
  • Desipramine / metabolism
  • Desipramine / pharmacology
  • Dopamine / pharmacokinetics
  • Enzyme Inhibitors / metabolism
  • Enzyme Inhibitors / pharmacology
  • Marine Toxins
  • Molecular Sequence Data
  • Myosin Light Chains / antagonists & inhibitors
  • Myosin Light Chains / metabolism
  • Naphthalenes / pharmacology
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / enzymology*
  • Norepinephrine / pharmacokinetics*
  • Norepinephrine Plasma Membrane Transport Proteins
  • Nucleic Acid Synthesis Inhibitors / pharmacology
  • Oxazoles / pharmacology
  • PC12 Cells
  • Peptide Fragments / chemistry
  • Peptide Fragments / genetics
  • Phosphorylation
  • Rats
  • Sympathomimetics / pharmacokinetics*
  • Symporters*
  • Tetradecanoylphorbol Acetate / pharmacology
  • Tritium
  • Wortmannin

Substances

  • Actins
  • Androstadienes
  • Calmodulin
  • Carcinogens
  • Carrier Proteins
  • Enzyme Inhibitors
  • Marine Toxins
  • Myosin Light Chains
  • Naphthalenes
  • Norepinephrine Plasma Membrane Transport Proteins
  • Nucleic Acid Synthesis Inhibitors
  • Oxazoles
  • Peptide Fragments
  • Slc6a2 protein, rat
  • Sympathomimetics
  • Symporters
  • Tritium
  • mycalolide B
  • Cytochalasin D
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Calcium-Calmodulin-Dependent Protein Kinases
  • calphostin C
  • Tetradecanoylphorbol Acetate
  • Calcium
  • Desipramine
  • Dopamine
  • Norepinephrine
  • Wortmannin